HUE070568T2 - Heterociklusos vegyületek rák kezelésében való alkalmazásra - Google Patents

Heterociklusos vegyületek rák kezelésében való alkalmazásra

Info

Publication number
HUE070568T2
HUE070568T2 HUE22797829A HUE22797829A HUE070568T2 HU E070568 T2 HUE070568 T2 HU E070568T2 HU E22797829 A HUE22797829 A HU E22797829A HU E22797829 A HUE22797829 A HU E22797829A HU E070568 T2 HUE070568 T2 HU E070568T2
Authority
HU
Hungary
Prior art keywords
cancer
treatment
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
HUE22797829A
Other languages
English (en)
Hungarian (hu)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam Mann
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Publication of HUE070568T2 publication Critical patent/HUE070568T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE22797829A 2021-10-21 2022-10-21 Heterociklusos vegyületek rák kezelésében való alkalmazásra HUE070568T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds

Publications (1)

Publication Number Publication Date
HUE070568T2 true HUE070568T2 (hu) 2025-06-28

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE22797829A HUE070568T2 (hu) 2021-10-21 2022-10-21 Heterociklusos vegyületek rák kezelésében való alkalmazásra

Country Status (24)

Country Link
US (1) US20240425511A1 (https=)
EP (2) EP4419526B1 (https=)
JP (2) JP2024539132A (https=)
KR (1) KR20240099274A (https=)
CN (2) CN119053600A (https=)
AR (1) AR127431A1 (https=)
AU (1) AU2022374050A1 (https=)
CA (1) CA3233255A1 (https=)
DK (1) DK4419526T3 (https=)
ES (1) ES3008687T3 (https=)
FI (1) FI4419526T3 (https=)
GB (1) GB202115156D0 (https=)
HR (1) HRP20250334T1 (https=)
HU (1) HUE070568T2 (https=)
IL (1) IL311922A (https=)
LT (1) LT4419526T (https=)
MX (1) MX2024004874A (https=)
PL (1) PL4419526T3 (https=)
PT (1) PT4419526T (https=)
RS (1) RS66620B1 (https=)
SI (1) SI4419526T1 (https=)
SM (1) SMT202500123T1 (https=)
TW (1) TW202334150A (https=)
WO (2) WO2023067355A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
PL4419526T3 (pl) 2025-04-22
SMT202500123T1 (it) 2025-05-12
LT4419526T (lt) 2025-03-25
EP4419527A1 (en) 2024-08-28
HRP20250334T1 (hr) 2025-06-06
US20240425511A1 (en) 2024-12-26
JP2024542949A (ja) 2024-11-19
DK4419526T3 (da) 2025-02-17
EP4419526A1 (en) 2024-08-28
ES3008687T3 (en) 2025-03-24
FI4419526T3 (fi) 2025-02-13
CA3233255A1 (en) 2023-04-27
PT4419526T (pt) 2025-02-03
RS66620B1 (sr) 2025-04-30
WO2023067355A1 (en) 2023-04-27
EP4419526B1 (en) 2024-12-25
CN119053600A (zh) 2024-11-29
IL311922A (en) 2024-06-01
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
KR20240099274A (ko) 2024-06-28
GB202115156D0 (en) 2021-12-08
WO2023067356A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
AU2022374050A1 (en) 2024-05-02
AR127431A1 (es) 2024-01-24
TW202334150A (zh) 2023-09-01
MX2024004874A (es) 2024-05-06

Similar Documents

Publication Publication Date Title
IL316706A (en) Macrocycle compounds for cancer treatment
IL288104B1 (en) Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer
IL290415A (en) Compounds with deuterium for use in cancer treatment
SI4419526T1 (sl) Heterociklične spojine za uporabo pri zdravljenju raka
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
ZA202206743B (en) Therapy for the treatment of cancer
IL280337A (en) LAG-3 combination therapy for cancer treatment
PL3601296T3 (pl) Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych
IL304595A (en) Bicyclic tetrahydrozepine derivatives for cancer treatment
IL307338A (en) Pyridinyl substituted oxisoisoindoline compounds for cancer therapy
IL312171A (en) Innovative use of the quinazolinone compound for cancer treatment
SMT202500434T1 (it) Sotorasib per l'uso nel trattamento del cancro
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL321393A (en) CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency
IL284162A (en) Integrated healing for cancer treatment
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
IL309172A (en) Vulbanazine for use in the additional treatment of schizophrenia
IL305780A (en) Cancer treatment methods
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
IL318816A (en) MTA-COOPERATIVE PRMT5 inhibitors for use in cancer treatment
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii
HK40115106A (en) Heterocyclic compounds for use in the treatment of cancer
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL286649A (en) The history of quinoline and its use in cancer treatment
GB202302121D0 (en) Compounds for use in the treatment of schizophrenia